Nitromethaqualone
(Synonyms: 硝甲喹酮) 目录号 : GC47781An Analytical Reference Standard
Cas No.:340-52-3
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Nitromethaqualone is an analytical reference standard categorized as a quinazolinone. This product is intended for research and forensic applications.
N/A
Cas No. | 340-52-3 | SDF | |
别名 | 硝甲喹酮 | ||
Canonical SMILES | CC(N1C2=C(OC)C=C([N+]([O-])=O)C=C2)=NC3=CC=CC=C3C1=O | ||
分子式 | C16H13N3O4 | 分子量 | 311.3 |
溶解度 | DMF: 20 mg/ml,DMSO: 20 mg/ml,Ethanol: 20 mg/ml,Ethanol:PBS (pH 7.2) (1:1): 0.5 mg/ml | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 3.2123 mL | 16.0617 mL | 32.1234 mL |
5 mM | 0.6425 mL | 3.2123 mL | 6.4247 mL |
10 mM | 0.3212 mL | 1.6062 mL | 3.2123 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Biotransformation and excretion of Nitromethaqualone in rats and humans
J Pharm Sci 1982 Oct;71(10):1152-7.PMID:7143214DOI:10.1002/jps.2600711019.
The metabolic disposition of 14C-labeled Nitromethaqualone was investigated in rats. Unlabeled Nitromethaqualone was used for studies on humans. Nitromethaqualone was eliminated from the body after most of it had undergone biotransformation. Both humans and rats reduced the nitro group of Nitromethaqualone to the corresponding amino derivative, which was partially transformed to the corresponding acetylated form. Cleavage of the quinazolinone nucleus resulting in 2-methoxyl-4-nitroaniline was also observed in humans. In rats additional major metabolites arose from the oxidation of the 2-methyl group into hydroxymethyl resulting in 2-hydroxymethyl-3-(2'-methoxy-4-nitrophenyl)-4(3H)-quinazolinone and concomitant in vivo reduction of the latter resulting in 2-hydroxymethyl-3-(2'-methoxy-4'-aminophenyl)-4(3H)-quinazolinone. Both metabolites were also excreted as glucuronides. In rats fecal excretion accounted for 55-60% of the administered dose, while 24-27% was excreted in the urine. Protracted excretion in both humans and rats indicated an extensive enterohepatic circulation.